Ciesco advises Vespa Capital’s investment in health communications firm Cognite
Summary
Ciesco was selected based on its strong senior-level relationships with an extensive buyer network including Private Equity firms, leading strategy consultants, advertising networks, financial and trade buyers, and specialist sector expertise.A specialist bio-tech communications firm, Cognite is entering a new growth phase, with plans to expand to the US and Asia and to increase its capabilities as a leading healthcare communications agency. Together, oncology and rare disease accounts for \xa31.6bn of the addressable market in 2021, forecast to grow to \xa32.6bn in 2025.CEO and founder of Ciesco, Chris Sahota, said: Were proud to have worked with Vespa Capital and Cognite to facilitate this investment. Headquartered in London and with a presence in Switzerland, the company has a unique track-record in rare diseases and speciality medicine, and offers leading insights into strategic positioning and optimisation throughout the product lifecycle.Lee Hurley, CEO of Cognite stated: In Vespa weve found the partner we need to complement our expertise and culture as we scale up. Headquartered in London, with offices in Germany and France and operating globally, Ciesco offers a unique combination at partnership level of senior industry practitioners and sector specialist investment bankers. Ciesco is well regarded in the market for its specialist advice derived from the deep understanding of the sector, industry and buyer landscape insights, and execution expertise.